InNexus Biotechnology Inc. Announces Dr. Capra Has Joined its Board of Directors

BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF)(TSX VENTURE:IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation (OMRF) and current InNexus Scientific Advisory Board (SAB) Chairman, joined its Board of Directors.

MORE ON THIS TOPIC